Ranibizumab Versus Low-fluence Photodynamic Therapy in the Treatment of Chronic Central Serous Chorioretinopathy

NCT01325181 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

34

Enrollment

OTHER

Sponsor class

Conditions

Chronic Central Serous Chorioretinopathy

Interventions

DRUG: Verteporfin
DRUG: ranibizumab

Sponsor

Jang Won Heo

Collaborators

[object Object]